NovaBay Pharmaceuticals
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2000-01-01
- Employees
- 8
- Market Cap
- -
- Website
- http://www.novabay.com
- Introduction
Niobay Metals Inc is engaged in the acquisition, exploration, and evaluation of mineral properties. Its project includes the James Bay Niobium Project located in northern Ontario, Canada. Its other projects include the Crevier niobium, the tantalum project, and Foothills.
Clinical Trials
8
Trial Phases
2 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (8 trials with phase data)• Click on a phase to view related trials
Efficacy of iLid Cleanser (Avenova) Versus Vehicle on Ocular Skin Flora
- Conditions
- Sebaceous Gland DiseasesBlepharitis
- First Posted Date
- 2015-05-28
- Last Posted Date
- 2015-05-28
- Lead Sponsor
- NovaBay Pharmaceuticals, Inc.
- Target Recruit Count
- 100
- Registration Number
- NCT02455895
- Locations
- 🇺🇸
Ophthalmic Research Consultants of Arizona, Phoenix, Arizona, United States
🇺🇸Turner Eye Institute, San Leandro, California, United States
🇺🇸James D. Branch, MD, Winston Salem, North Carolina, United States
Efficacy Study of Auriclosene Irrigation Solution on Urinary Catheter Patency
- Conditions
- Urinary Catheter Blockage and Encrustation
- Interventions
- First Posted Date
- 2014-05-05
- Last Posted Date
- 2015-12-02
- Lead Sponsor
- NovaBay Pharmaceuticals, Inc.
- Target Recruit Count
- 140
- Registration Number
- NCT02130518
- Locations
- 🇺🇸
Los Amigos Research and Education Institute, Downey, California, United States
🇺🇸VA Long Beach Healthcare System, Long Beach, California, United States
🇺🇸Southern California Permanente Medical Group, Los Angeles, California, United States
Efficacy and Safety of Auriclosene (NVC-422) in the Treatment of Bacterial Conjunctivitis
- Conditions
- Bacterial Conjunctivitis
- Interventions
- First Posted Date
- 2013-06-14
- Last Posted Date
- 2015-05-28
- Lead Sponsor
- NovaBay Pharmaceuticals, Inc.
- Target Recruit Count
- 217
- Registration Number
- NCT01877694
Vehicle Controlled Efficacy and Safety Study of Two Dose Regimens of CD07223 1.5% Topical Gel in Impetigo
- Conditions
- Impetigo
- First Posted Date
- 2012-08-21
- Last Posted Date
- 2014-08-12
- Lead Sponsor
- NovaBay Pharmaceuticals, Inc.
- Target Recruit Count
- 328
- Registration Number
- NCT01670032
- Locations
- 🇺🇸
SRCR, Inc, Bell Gardens, California, United States
🇺🇸Skin Care research Inc, Boca Raton, Florida, United States
🇺🇸Eastern Research, Inc, Hialeah, Florida, United States
Efficacy and Safety of NVC-422 in the Treatment of Adenoviral Conjunctivitis
- Conditions
- Adenoviral Conjunctivitis
- Interventions
- Drug: NVC-422 Solution, 0.3%Drug: NVC-422 Vehicle Solution
- First Posted Date
- 2012-02-14
- Last Posted Date
- 2015-05-28
- Lead Sponsor
- NovaBay Pharmaceuticals, Inc.
- Target Recruit Count
- 500
- Registration Number
- NCT01532336
- Prev
- 1
- 2
- Next
News
FDA Clears NovaBay's Novel Dual-Action Eye Infection Treatment NVC-422 for Clinical Trials
NovaBay Pharmaceuticals receives FDA clearance for Investigational New Drug application of NVC-422, triggering a $1 million milestone payment from licensing partner Alcon.